Amgen profit beats estimates, next MariTide studies start by mid-year
Portfolio Pulse from
Amgen reported a higher quarterly profit due to an 11% increase in product sales. The company plans to start late-stage studies of its obesity drug candidate MariTide by mid-year, although an early-stage trial of another weight-loss drug is on hold.
February 04, 2025 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's quarterly profit exceeded expectations due to increased product sales. The company is advancing its obesity drug MariTide to late-stage trials, although another drug trial faces regulatory hold.
Amgen's strong earnings report and the advancement of MariTide to late-stage trials are positive indicators for the company's growth prospects. However, the regulatory hold on another drug trial introduces some uncertainty.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100